INTRODUCTION
A revisões cribed anxiolytics were alprazolam and lorazepam. 2, 4 A Portuguese study from 2004 showed that the annual prevalence of BZD use among a population served by one health center in the North region was 14.8% and that the number of patients seeking medical attention and taking BZD was threefold that of non-users. 5 Another Portuguese study reported that up to 23% of adult patients registered and consulted within a period of 12 months at a Health Center in the Lisbon periphery were taking BZD. 6 At the primary care level, a study revealed some heterogeneity of criteria used to support the decision of when and which BZD should be prescribed. 7 A narrative review was conducted and the most relevant information about BZD indications, adverse effects, and risks of overprescription/overuse are reported in this paper. In addition, the most relevant approaches to support BZD withdrawal at the primary care level are also explored. This review is part of a novel program aimed at helping family doctors in Portugal to prevent BZD inadequate use and to support patients to cease its consumption.
METHODS
A literature review was conducted on sources of scientific peer-reviewed articles, textbooks and health organizations' reports and recommendations. For the comprehensive assessment of the relevant articles, we privileged original research in outpatient clinics or community settings, independently rated as high-quality studies, reviews or guidelines. The search had no temporal limit. We searched for documental and electronic data sources, including a structured search of MEDLINE, using the following Medical Subject Headings (MeSH) terms: benzodiazepines, withdrawal, adverse effects, and primary care. The review was restricted to papers published in English, Spanish, or Portuguese.
RESULTS

General principles for BZD prescription
BZD have six main properties and clinical relevant actions: anxiolytic, hypnotic, anticonvulsant, muscle relaxant, anterograde and retrograde amnesia and alcohol withdrawal. 8 Their approved indications for the anxiolytic and hypnotic effects are reflected in the recommendations from several health authorities, like the British National Health Service (NHS) or the Portuguese Directorate-General of Health (DGS): [8] [9] [10] • BZD are indicated in anxiety and insomnia when the disorder is severe, disabling or subjecting the individual to extreme distress. • Treatment should start with the lowest recommended dose in order to prevent dependence, and when a prescription decision is taken, it is recommended to monitor treatment every two weeks. • Duration of BZD use should be as short as possible, not exceeding eight to 12 weeks for anxiety or four weeks for insomnia. This time period should include tapering off process. • If the extension beyond the maximum treatment period is necessary, the patient should be evaluated and specialized advice may be necessary. • The patient must be informed about the short-term duration of therapy and should be instructed about the most adequate tapering off process. Patients must be aware of the rebound phenomena, in order to minimize anxiety symptoms during dose reduction period. Psychotherapy is recommended as the first approach to anxiety symptoms, ultimately associated or not with psychotropic drugs. In cases of anxiety with depression, it is recommended to prescribe antidepressants as firstline treatment. A BZD for a period up to three or four weeks may be necessary. Antidepressants are usually not associated with significant tolerance or dependence. 11 Table 2 presents the main contraindications to be considered when prescribing a BZD. Table 3 summarizes some of the problems associated with BZD consumption. Adverse consequences of BZD are usually dose-related and predictable. More serious adverse effects can result from long-term regular use in therapeutic dosage and from self-prescription or recreational use in excessive doses. 12 Anterograde amnesia occurs a few hours after administration, especially with hypnotics at higher doses. For this reason, it should be recommended a continuous sleep of seven to eight hours after the intake. It remains unclear whether the usage of BZD induces cognitive impairment after discontinuation, especially in the elderly. 13 Some studies have shown a positive asso-revisões ciation between BZD and Alzheimer's disease, especially for long-acting substances and when higher doses are used. Although this is still controversial, some authors suggest that BZD use can be an early marker of dementia. [14] [15] Exposure during fetal life has been suggested to contribute to neonatal morbidity and some congenital malformations like orofacial clefts, preterm birth, and low birth weight. The majority of congenital malformations are moderately increased in infants exposed in early pregnancy. 13 When used in the late phase of pregnancy, or during labor at high doses, effects on the neonate, such as hypothermia, hypotonia or moderate respiratory depression, can be expected. 8 Some may also develop physical dependence and may be at risk for withdrawal symptoms in the postnatal period up to one-month post-delivery, as well as a possible longterm impact on neurodevelopment. 8 Some loss of efficacy of BZD may develop after repeated use. The rate of development of tolerance may vary for different drug effects, can develop at different speeds, and can vary between individuals. Prescribing for people who are using high doses and those who use illicit drugs develop a tolerance quickly and will often escalate their dose. 8 The tolerance to the hypnotic effects tends to develop more rapidly than to the anxiolytic effect, which occurs at a slower rate. 16 The risk of physical and psychological dependence increases with frequent long-term, high-dose users. It is also higher in patients with a history of other drug abuse. 8 Physical dependence is common in patients on longterm treatment, even at therapeutic dosages. 13 Once physical dependence has developed, abrupt termination of treatment will be accompanied by withdrawal symptoms (Table 4 ). Many studies have shown that between 20 to 100% of patients taking BZD are physically dependent and will experience withdrawal symptoms upon abrupt discontinuation. 12 Some patients are going to experience withdrawal symptoms even with therapeutic doses, which may induce the prescription of higher doses. 16 Individual risk factors for the development of dependence are not well understood but seem to include diagnosis of mental disease, male gender, younger age, low education level, being single or homeless, with a family history of substance abuse, being imprisoned and having antisocial personality disturbance. 11, 17 Continuing medical education (CME) objectives:
Problems associated with BZD use
• To alert the health community on the evidence about BZD overuse/misuse and its risks.
• To improve medical literacy regarding BZD indications, its adverse effects, and risks of over-prescription, including long-term use. • To explore available approaches to discontinue BZD at the primary care level.
Key summary points:
• BZD may have a role as anxiolytics and hypnotics when the disorder is severe, disabling or subjecting the individual to extreme distress. Treatment should be as short as possible, not exceeding eight to 12 weeks for anxiety or four weeks for insomnia, including a tapering off process. • It is mandatory that the deleterious effects of BZD' long-term use are detected and addressed as a way to prevent dependence and withdrawal syndrome. • Awareness and motivation of both doctors and patients is the first step for reducing BZD' adverse effects.
• The most important measure for the prevention of inappropriate prescription is the motivation for discontinuing therapy and its supervision. revisões The risk of overdose when combined with other sedative substances such as alcohol, opioids, antipsychotics, and antidepressants must be taken into account, because of the central nervous system (CNS) depressant effect. 8 The elderly are more sensitive to the CNS effects of BZD, developing more frequently effects, like confusion, amnesia or ataxia. 10 Short-acting BZD proved to be an independent risk for falls, which is higher as it is increased the risk of receiving a new prescription: number of physicians seen at baseline, being female, having a diagnosis of arthritis, depression or alcohol abuse. 13 
Overprescription of BZD
The prevalent use of BZD represents a worldwide problem, despite their perceived favorable safety profile by both patients and doctors. 12, 16 It is estimated that only a third of BZD prescriptions in the elderly are considered appropriate. 18 BZD are among the most common potentially inappropriate drugs for older persons, including NSAIDs, antihistamines, and antipsychotics. 19 Some studies have pointed out reasons that lead to the use of BZD for longer periods than recommended: 7, 11, 20 • Effectiveness in eliminating or reducing symptoms; • Patients' fear of withdrawal symptoms; • Patients' desire for rapid symptoms relieve puts more pressure on medical prescription; • Difficult access to psychotherapy, which may indicate that this type of health care needs is not being met; • Lack of patients' awareness regarding the risks of BZD use; • «Medicalization» of human daily worries; • The over-optimistic safety profile of BZD, also promoted by pharmaceutic industry (when first launched in the market in the '60s). An inappropriate prescription may be prevented by revisões simple intervention measures: 10, 21 • Careful selection of patients that benefit from BZD prescription; • Clear definition of therapeutic goals; • Frequent reconciliation of medication lists; • Improvement of patients' knowledge about the benefits and risks of BZD use; • Use of tools like electronic alerts and Beers' or STOP/START criteria, when considering the elderly population. • Withdrawing from BZD.
BZD duration of action may affect the frequency and course of withdrawal. 22 With short-acting BZD, the withdrawal symptoms typically begin one-two days after the last dose and continues for two-four weeks or longer. With long-acting BZD, the withdrawal may begin two-seven days after the last dose and continues for two-eight weeks or longer.
Many studies have been conducted in order to evaluate efficient measures to stop BZD long-term intake: • The Eliminating Medications through Patient Ownership of End Results (EMPOWER) study in Canada found that an educational booklet about BZD resul-ted in drug cessation at six months in 27% of the patients versus 5% with usual care. The dose reduction was an additional 11% versus 6%. This intervention also recommended discussing BZD use with a physician or pharmacist. 23 • One meta-analysis showed that withdrawal interventions plus psychotherapy, prescribing interventions (e.g., medication review, consultation, or education) or multifaceted prescribing interventions, reduced the use of BZD when compared with control. Single-facet prescribing interventions and withdrawal interventions plus drug therapy did not reduce BZD use. The benefit of withdrawal interventions plus psychotherapy was maintained at three months of follow-up. 11 • A systematic review found evidence for the efficacy of stepped care (minimal intervention followed by tapering off program) in discontinuing long-term BZD use. 24 • Another review found evidence for a simple letter intervention. It showed to reduce long-term BZD usage in older patients with one cessation of BZD for every 12 letters sent. Despite the modest percentage, the minimal effort required suggests that it would have a high benefit-to-effort ratio. 25 Withdrawal symptoms can take almost any psychological and/or somatic form, but can be considered as falling into three main groups:
• Anxiety symptoms:
-Psychological: anxiety, panic attacks, poor memory, depression, paranoia, intrusive memories, cravings, nightmares, excitability, social and agoraphobia, obsessions, irritability; -Physical: agitation, tremor, headache, weakness, dizziness, nausea, vomiting, diarrhea, constipation, palpitations, rashes, fatigue; • Distorted perceptions: hypersensitivity to sound, light, touch, abnormal body sensations, depersonalization; • Major incidents: fits, delirium (rare), hallucinations, psychosis (very rare).
How to withdraw?
Some health organizations, including the World Health Organization, propose a withdrawal schedule, in which the first step is to stabilize the patient on an equivalent dose of diazepam.
1. Calculate how much diazepam is equivalent to the daily dose of BZD that the patient currently uses. 2. The length of time between each dose reduction should be based on the presence and severity of withdrawal symptoms (the longer the interval between reductions, the more comfortable and safer the withdrawal). Generally, there should be at least one week between dose reductions. 3. It is not recommended to increase the dose when symptoms worsen; instead, persist with the current dose until symptoms abate, then continue with the dose reduction schedule. 4. Patients should be offered psychological care to address these symptoms. 
revisões
• One primary care multicenter study suggested that a structured and individualized intervention with a written plan for the gradual reduction of the dose is less time-consuming and as effective as more complex interventions with follow-up appointments. 26 Another meta-analysis in the UK also concluded that a brief intervention with a flyer or a single consultation with the family doctor, for long-term users, are effective and efficient strategies to interrupt or reduce BZD, without adverse effects, with a necessary 12 contacts for one therapeutic cessation. 25 • One study in a Portuguese health center showed a positive association between psychological support and lower BZD consumption, with lower costs and as an alternative to pharmacological intervention. 7 Another study concluded in favor of the benefit of combined intervention with group cognitive-behavioral therapy and reduction of dose in patients with insomnia and long-term treatments. Cessation of therapy was maintained after one year. 27 In line with the above-mentioned results, it has been described that the success of discontinuing therapy in long-term users seems to be associated with the perception of self-efficacy, beliefs about withdrawal symptoms and initial motivation to quit. 28 In fact, one study showed that patients choose to terminate consumption when they are well informed about the risks of BZD and when proposed a calendar for discontinuation. 23 It is also consensual that the safest way to manage BZD withdrawal is to gradually decrease the dose ( Table 4 ). This helps to avoid or at least reduce withdrawal symptoms. 13 The risk of withdrawal phenomena is higher after abrupt discontinuation of treatment because of the sudden decrease in γ-aminobutyric acid (GABA) signaling. 8, 29 Official guidelines in Portugal recommend that patients should be referred to intramural detoxification programs when using doses higher than 30 or 50mg of diazepam or equivalent on a daily basis. Reference should be considered in presence of antisocial personality disorder, history of seizures as a withdrawal symptom, previous unsuccessful regimens of detoxification, when it is the patient preference or in case of codependency of other drugs. 10, 30 
CONCLUSIONS
Despite the well-established risks linked with long-term use, BZD continue to be widely prescribed and Portugal is one particular example of their high utilization rate.
BZD are remarkably useful drugs in short-term, occasional, or intermittent use. Adverse effects are recognized as significant risks in patients receiving treatment for longer than recommended. It is paramount to adopt strategies in order to prevent inadequate use of BZD, such as: cautious appraisal of the need for prescription, provision of educational information to the patient, use of the lowest dose possible and for the shortest time, assessment of efficacy in every consultation, and inclusion of information on gradually discontinuing the dose. Before prescribing, contraindications should always be considered and non-pharmacological or alternative pharmacological interventions should be envisaged. There are several guidelines recommending the use of other-than-BZD based therapies, including psychotherapy.
BZD discontinuation should be agreed by the doctor and patient. Structured approaches for long-term users, including brief intervention and engagement in gradual dose reduction programs, have shown good results, with additional benefit if associated with psychological support. 31 Further research may help to better characterize predictive factors associated with BZD misuse, as well as to shed light on the impact of health programs aimed at helping long-term users to cease consumption at the primary care level.
revisões
RESUMO
PRESCRIÇÃO E DESCONTINUAÇÃO DE BENZODIAZEPINAS EM CUIDADOS DE SAÚDE PRIMÁRIOS
A utilização crónica de benzodiazepinas ansiolíticas ou hipnóticas é um tema controverso e visto como um problema de saúde pelos médicos de família. Objectivos: Rever as indicações, efeitos adversos e riscos associados à sobreutilização de benzodiazepinas. São também exploradas algumas estratégias para a descontinuação destes fármacos em cuidados de saúde primários. Métodos: Revisão bibliográfica com pesquisa estruturada na MEDLINE e outras publicações sobre o tema da prescrição e sobreutilização de benzodiazepinas, bem como protocolos de descontinuação relevantes para os cuidados de saúde primários. Resultados e conclusões: Embora as recomendações nacionais e internacionais estejam alinhadas quanto às indicações e efeitos adversos das benzodiazepinas em utilização prolongada, estudos revelam uma sobreutilização preocupante destes fármacos em Portugal. As principais indicações das benzodiazepinas são a ansiedade e insónia em situações de doença grave, limitante ou que exponha o doente a elevados níveis de stress. O tratamento deve ser tão curto quanto possível, não ultrapassando as oito a doze semanas em casos de ansiedade e as quatro semanas nos casos de insónia. Existe evidência de bons resultados recorrendo a abordagens sistemáticas que incluam intervenções breves, acompanhadas da redução gradual da dose utilizada de benzodiazepinas. Esta revisão constitui o primeiro passo para o desenvolvimento, implementação e avaliação da efetividade de um programa de descontinuação gradual a ser disponibilizado aos médicos de família em Portugal.
